Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex-Reference-Cited by-同舟云学术

Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex

Published:2023-09 Issue:5 Volume:3 Page:100214
ISSN:2667-0267
Container-title:JID Innovations
language:en
Short-container-title:JID Innovations

Author:

Tollenaere Maxim A.X.^ORCID,Mølck Christina^ORCID,Henderson Ian^ORCID,Pollack Scott^ORCID,Addis Philip^ORCID,Petersen Helle Heibroch^ORCID,Norsgaard Hanne^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference37 articles.

1. cDNA cloning and characterization of the human interleukin 13 receptor alpha chain;Aman;J Biol Chem,1996

2. Kinetic analysis of the interleukin-13 receptor complex;Andrews;J Biol Chem,2002

3. IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts;Andrews;J Allergy Clin Immunol,2006

4. TNF-α/IL-17 synergy inhibits IL-13 bioactivity via IL-13Rα2 induction;Badalyan;J Allergy Clin Immunol,2014

5. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis;Bieber;Allergy,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type 2 cytokine-dependent skin barrier regulation in personalized 2D- and 3D skin models of atopic dermatitis: A pilot study;JID Innovations;2024-08

2. Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab;Dermatology Practical & Conceptual;2024-07-31

3. Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma;Life;2024-02-09

4. A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults;Expert Review of Clinical Immunology;2023-11-13

5. Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL‐13 inhibition;Allergy;2023-07-16